MGFA has partnered with Bionews to feature the “Myasthenia Gravis News” feed on our MGFA website. We are excited to offer the MG Community this insightful and informative news feed that covers many aspects of living with myasthenia – from research and study results to managing MG, helpful tips, and important news from across the MG World.
Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, BioNews seeks the opinion of outside experts for interviews and Q&As.
Myasthenia Gravis News – The Web’s Daily Resource for Myasthenia Gravis News
- How I manage my image to live with myasthenia gravisby Sarah Bendiff on April 17, 2025 at 2:00 pm
I recently made peace with the fact that we almost always judge the book by its cover. It’s just what humans do. We believe what we see. And having a The post How I manage my image to live with myasthenia gravis appeared first on Myasthenia Gravis News.
- Symptoms of gMG controlled with long-term nipocalimab treatmentby Marisa Wexler, MS on April 17, 2025 at 12:00 pm
Long-term treatment with nipocalimab led to sustained reductions in symptom severity among antibody-positive patients with generalized myasthenia gravis (gMG) in a Phase 3 clinical trial. That’s according to new data The post Symptoms of gMG controlled with long-term nipocalimab treatment appeared first on Myasthenia Gravis News.
- Telitacicept found to reduce gMG severity in Phase 3 trial in Chinaby Andrea Lobo on April 16, 2025 at 4:45 pm
Treatment with Remegen’s telitacicept over nearly six months safely reduced disease severity in adults with generalized myasthenia gravis (gMG) and helped ease these patients’ symptoms. That’s according to new data The post Telitacicept found to reduce gMG severity in Phase 3 trial in China appeared first on Myasthenia Gravis News.
- Vyvgart Hytrulo prefilled syringe gets US regulatory approvalby Lindsey Shapiro, PhD on April 15, 2025 at 12:00 pm
The U.S. Food and Drug Administration (FDA) has approved a version of Argenx’s Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that can be self-administered via a prefilled syringe to treat generalized The post Vyvgart Hytrulo prefilled syringe gets US regulatory approval appeared first on Myasthenia Gravis News.
- 30 minutes to Roz: How bulbar muscle weakness affects my voiceby Shawna Barnes on April 14, 2025 at 2:00 pm
“I’m watching you, Wazowski. Always watching.” If you’re a cartoon fiend like I am, you likely recognize that quote from “Monsters, Inc.,” said by Roz, an administrator. Roz has a The post 30 minutes to Roz: How bulbar muscle weakness affects my voice appeared first on Myasthenia Gravis News.
** MGFA Disclaimer – Please read
Myasthenia Gravis Foundation of America (MGFA) and Bionews, Inc. (specifically Myasthenia Gravis News) have entered into a limited agreement that allows for the MGFA to post a link to Myasthenia Gravis News on the myasthenia.org website. Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, Bionews seeks the opinion of outside experts for interviews and Q&As.
The publishing team at Myasthenia Gravis News is made up of science writers and editors, most of whom have PhDs in the life sciences; veteran journalists; and columnists who are members of the MG community. Together, they attempt to ensure that all content published on Myasthenia Gravis News is relevant, accurate, informative, relatable, and easy to understand.
Each piece of content is carefully selected and written by Bionews writers with the MG community in mind. Sources for news stories and resource pages include peer-reviewed studies, press releases, announcements, interviews, webinars, and conference sessions, among others. All articles go through a stringent fact-checking and editing procedure as part of Bionews’ process to ensure they are accurate, objective, comprehensive, and well-explained.
Columns are written by MG patients and caregivers who provide an intimate look at what it’s like to live with the disease. While columns are largely opinion and perspective pieces, each one still goes through a comprehensive editing and fact-checking process by Bionews editors to ensure clarity, accuracy, and fairness.
Myasthenia Gravis News’ site is strictly a news and information website about the disease. It DOES NOT provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The information provided is for educational purposes only and does not substitute for professional medical advice.
The content reflects the unique experiences of the authors and is not necessarily the opinion, views, or recommendations of the MGFA. Medical advisors and clinicians associated with or partnering with the MGFA do not peer review articles and information posted on the Myasthenia Gravis News platform or website. MGFA should not be liable for any information, opinions, articles, advice, guidance, or details posted on the Myasthenia Gravis News site. MGFA has posted this platform as a service to the MG community. Please consult with your doctor and healthcare professionals for specific recommendations and advice pertaining to your healthcare/treatment.
English
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Russian
Spanish